報價延遲最少15分鐘:2025/02/22 17:43 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.01 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.45/-0.50
|
|
企業價值
311.91M
|
| 資產負債 |
|
每股賬面淨值
-0.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
50.58M
|
|
每股收益
0.53
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/22 17:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. |